2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 993

pH-Sensitive Nanoformulated Triptolide as a Targeted Therapeutic Strategy for Rheumatoid Arthritis
Abstract Number: 2058

Pharmacoepidemiology of Gout Treatment in Office-based Outpatient Care from 2009- 2016
Abstract Number: 1694

Pharmacogenetics and Pharmacodynamics of Response to Apremilast in a Phase 3 Clinical Study in Subjects with Active Behçet’s Disease
Abstract Number: 2565

Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus
Abstract Number: 2668

Pharmacokinetics and Pharmacodynamics of Tocilizumab in Combination with Prednisone Tapering in Patients with Giant Cell Arteritis: 3-Year Results from a Randomized Controlled Phase 3 Trial
Abstract Number: 2541

Pharmacokinetics of Hydroxychloroquine in Systemic Lupus Erythematosus Patients with Renal Impairment
Abstract Number: 2580

Pharmacotherapies Targeting Type 2 SLE Symptoms
Abstract Number: 1217

Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development
Abstract Number: 530

Phase I Evaluation of the PDE4 Inhibitor LY2775240: Head to Head Comparison with Apremilast Using an Ex Vivo Pharmacodynamic Assay
Abstract Number: 48

Phenotype-based Clustering Along with Analysis of Molecular Profile Might Help to Define Precise CV-risk Profiles in RA Patients
Abstract Number: 2259

Physical Challenges in RA: A Qualitative Study of an Online Patient Support Group
Abstract Number: 1845

Physical Inactivity Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus
Abstract Number: 954

Physical Therapy and Opioid Use in Knee Osteoarthritis
Abstract Number: 1128

Physician-Patient Interaction and Medication Adherence in Lupus Nephritis
Abstract Number: 1061

PI3K-Akt Pathway Plays a Crucial Role in Production of Collagen in Fli1 Deficient Condition and Its Inhibitor Has the Therapeutic Potential in Treating Fibrosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].